US SEC Filing Intelligence

Defense Manufacturing Contracts — September 05, 2026

This digest covers a single, high-value civilian space contract: a $660 million firm-fixed-price award from NASA to Blue Origin, LLC for the Mars Sample Return mission. The contract is entirely civilian (NASA), with no defense-related obligations, and represents a significant competitive win for Blue Origin in deep-space exploration. The highest-conviction signal is the bullish competitive moat implied by Blue Origin winning a full-and-open competition against major primes, though the high-risk fixed-price structure and lack of outlayed funds present execution risk. Key watch items include NASA budget stability for the Mars Sample Return program and Blue Origin's milestone performance under fixed-price terms.

DHS Homeland Security Contracts — September 05, 2026

This digest covers a single DHS contract awarded to PAE Professional Services LLC (a subsidiary of Amentum Holdings Inc.) valued at $224.5 million in total obligation, with no defense-related exposure. The contract, a firm-fixed-price award from USCIS for Application Support Center operations, carries a neutral signal due to its competitive nature and stable civilian agency funding, but execution risk is elevated given the fixed-price structure and only $59.1 million outlayed against the full obligation. The highest-conviction signal is the potential underperformance or delayed funding, which warrants monitoring for margin pressure on Amentum. Key risks include high pricing risk from the fixed-price contract and uncertainty around contract modifications beyond the September 2023 end date.

New Federal Contractors — September 05, 2026

This digest covers four contracts totaling $1.49 billion, with only one defense-related award (25% of total) and three civilian contracts. The dominant theme is NASA's deep-space exploration investment, led by a $660 million fixed-price contract to Blue Origin for Mars Sample Return, which is the highest-conviction signal. However, execution risk is elevated due to the fixed-price structure and no initial funding outlay. Civilian contracts from GSA, DHS, and GSA for IT and logistics services are neutral, with legacy or maturing periods limiting forward revenue visibility. Key risk is the lack of funded milestones on the Blue Origin contract, which could delay or reduce scope.

Significant Contract Modifications ($10M+) — September 05, 2026

This digest covers $1.49 billion in total obligations across four contracts, with only one defense-related award (25% defense/civilian split). The dominant theme is civilian agency spending on deep-space exploration, IT services, and logistics, led by a $660 million Blue Origin NASA contract for Mars Sample Return—the highest-conviction signal. However, three of four contracts carry high pricing risk (fixed-price), and the aggregate signal strength is moderate (5.5/10). Key risk: Blue Origin’s fixed-price structure and zero funds outlayed to date create execution uncertainty, while legacy contracts from GDIT and PAE/Amentum offer limited forward revenue visibility.

Contract Deobligations Alert — September 05, 2026

The September 5, 2026 contract deobligations digest totals $1.49 billion across four awards, with a 25% defense-related mix (1 of 4 contracts). The dominant theme is civilian space and services, led by a $660 million NASA award to Blue Origin for Mars Sample Return, which is the highest-conviction signal (bullish, 7/10) but carries high execution risk due to its fixed-price structure and no outlayed funds. Other awards include a legacy GDIT cost-plus contract for NAVAIR engineering, a PAE (Amentum) fixed-price USCIS contract with potential underperformance, and a GSA small business win for pharmaceutical logistics. Key watch items include NASA budget risks for Mars Sample Return, option exercises on the GSA contract, and the maturing GDIT contract's recompete potential.

Contract Option Exercises — September 05, 2026

This digest covers $1.487 billion in contract obligations from September 5, 2026, with a 1/4 defense ratio and an average signal strength of 5.5/10. The dominant theme is non-defense space and civilian services, led by a $660 million NASA award to Blue Origin for Mars Sample Return that carries a 7/10 bullish signal but high execution risk due to firm-fixed-price structure and zero funds outlayed. A $440 million GDIT legacy NAVAIR cost-plus contract (awarded 2017) offers low-margin stability but limited forward visibility. A $224.5 million Amentum/PAE USCIS application support contract poses margin risk under fixed-price terms with only 26% funds outlayed. The highest-conviction signal is Blue Origin’s competitive win in deep-space exploration, but the primary risk is NASA budget cuts threatening Mars Sample Return funding.

Federal Professional Services Contracts — September 05, 2026

The single contract in this period, a $440.5M obligated cost-plus award fee delivery order to General Dynamics Information Technology (GDIT) from GSA for NAVAIR CSM engineering services, represents a legacy award with limited forward-looking investment impact. While the contract is entirely defense-related and signals stable revenue for GDIT through its 2021-2022 end dates, the low outlay ($33M) relative to total value suggests execution is in early stages. The neutral signal strength and low materiality score indicate this is not a near-term catalyst for General Dynamics (GD). The primary risk is the contract's maturity, with no clear follow-on or re-compete data provided, creating a revenue gap risk for GDIT's defense electronics and systems integration segment.

Federal IT & Cybersecurity Contracts — September 05, 2026

In the single contract recorded for September 05, 2026, the Department of Homeland Security (DHS) awarded Amentum Holdings Inc.'s subsidiary, PAE Professional Services LLC, a $224.5 million obligation under a $556.6 million firm-fixed-price contract for USCIS Application Support Center operations. This is a purely civilian award with no defense-related contracts in the stream, underscoring the non-defense budget environment. The contract shows a neutral signal with high execution risk due to the fixed-price structure and only $59.1 million outlayed against the total obligation, suggesting potential underperformance or delayed funding. The key watch item is the contract's September 2023 end date, which has already passed, raising questions about extensions or recompetes that could impact Amentum's revenue stability.

NASA & Space Contracts Intelligence — September 05, 2026

NASA awarded Blue Origin, LLC a $660,000,017 firm-fixed-price contract for the Mars Sample Return mission and future Mars exploration, marking a significant civilian space win for the company. This is the sole contract in the period, entirely civilian (0/1 defense-related), with a strong bullish signal (7/10). The award underscores NASA's sustained commitment to deep-space infrastructure, but the fixed-price structure and lack of initial funding outlay introduce execution and budget risks. Blue Origin's competitive win in a full-and-open competition signals its growing capability in deep-space systems, though investors should monitor milestone progress and NASA budget dynamics closely.

Mega Contracts Monitor ($100M+) — September 05, 2026

This digest covers $1.49 billion in total obligations across four contracts, with only one defense-related award (25% of total), signaling a civilian-heavy procurement period dominated by NASA's $660 million Mars Sample Return contract to Blue Origin. The highest-conviction signal is bullish for Blue Origin's competitive win in deep-space exploration, though the fixed-price structure and zero initial outlay pose execution risk. Civilian contracts from GSA and DHS total $827 million, but legacy awards from 2017-2018 (GDIT, PAE) offer limited forward visibility. Key risks include fixed-price margin pressure on Blue Origin and Integrated Quality Solutions, and budget uncertainty for NASA's Mars program.

High-Value Federal Grants ($5M+) — September 05, 2026

This digest covers $1.487 billion in total obligations across four contracts, with only one (25%) defense-related award, underscoring a civilian-heavy procurement theme. The highest-conviction signal is Blue Origin's $660 million NASA Mars Sample Return contract, a bullish deep-space exploration win that strengthens its competitive moat but carries high fixed-price execution risk. The remaining three contracts—General Dynamics IT ($440M, legacy NAVAIR engineering), Amentum/PAE ($224M, USCIS application support), and Integrated Quality Solutions ($162M, GSA pharmaceutical logistics)—are neutral signals with limited forward-looking impact due to maturing periods or fixed-price margin pressure. Key risk: Blue Origin's contract has zero funds outlayed, making it vulnerable to NASA budget reallocations or CR delays.

General Federal Contracts — September 05, 2026

This digest covers $1.487 billion in federal contracts awarded between 2017 and 2026, with only one of four contracts defense-related (General Dynamics Information Technology's $440M NAVAIR engineering services award), indicating a civilian-heavy period. The dominant theme is NASA's deep-space exploration push, led by Blue Origin's $660M firm-fixed-price Mars Sample Return contract—the highest-conviction signal despite execution risk from zero initial funding. Key risks include fixed-price pressure on Blue Origin and Integrated Quality Solutions, and legacy contract maturity for GDIT. Investors should watch NASA budget stability and Blue Origin's milestone progress as primary catalysts.

All NASA Contracts — September 05, 2026

This digest covers a single, high-materiality NASA contract awarded to Blue Origin, LLC valued at $660 million for Mars Sample Return and exploration missions. The total obligation is entirely civilian (NASA), with no defense-related spending. The dominant theme is deep-space exploration infrastructure, and the highest-conviction signal is Blue Origin's competitive win in a full-and-open competition, strengthening its position against rivals. Key risks include the fixed-price contract structure with no initial funds outlayed, execution milestones, and potential NASA budget cuts to the Mars Sample Return program.

Biotech Small-Cap Approvals — September 04, 2026

The September 4, 2026 approval digest contains 5 biosimilar/other approvals and zero NMEs, zero biosimilars (by formal designation), and zero label expansions, tilted entirely toward generic competition in mature drug classes. Two sponsors—DR REDDYS and SPIL—received simultaneous biosimilar/other approval for POMALIDOMIDE, a multiple myeloma therapy originally commercialized by BRISTOL MYERS SQUIBB, signaling an aggressive wave of multiple entrant competition. The digest lacks any high-value NME or breakthrough therapy catalysts, and all approvals are rated neutral/5/10, providing no sector-moving bullish or bearish signals. Investors should watch for accelerated revenue erosion for originator Pomalyst/Imnovid as two ANDA players enter the market, and for TEVA PHARM’s entry into the elagolix+estrogen franchise (originally AbbVie’s Orilissa), a signal of incremental generic pressure in endometriosis therapeutics. The single-period concentration on pomalidomide generics warrants a cautious near-term posture on Bristol Myers Squibb’s hematology revenue stream.

5 total filings

New Drug Approvals (Original) — September 04, 2026

The September 4, 2026, FDA new drug approval stream recorded five approvals, all classified as 'FALLBACK' (likely generic/biosimilar follow-ons), with zero NMEs, zero novel biosimilars, and zero label expansions. The dominant theme is generic/biosimilar competition in established therapeutic categories: two approvals of POMALIDOMIDE (Dr. Reddy’s / SPIL) create a direct threat to the originator (Bristol Myers Squibb’s POMALYST), and one approval of ELAGOLIX/estradiol/norethindrone acetate (Teva) challenges AbbVie’s ORILISSA franchise. Qilu Pharma’s DIFELIKEFALIN ACETATE and Macleods’ MAGNESIUM SULFATE are niche generic entries. The highest-conviction signal is the dual POMALIDOMIDE approval, accelerating generic erosion of a $700M+ oncology asset. Key risk: investor overexposure to BMS’s POMALYST revenue stream, and AbbVie’s ORILISSA facing new low-cost competition. No IRA exposure flags are triggered from these specific approvals, but the data confirms ongoing margin compression in small-molecule oncology and women’s health segments.

5 total filings

Federal Construction & Infrastructure Contracts — September 04, 2026

The sole contract in this digest is a $484.2 million firm-fixed-price award from the Department of State to Caddell Construction Co. (DE), LLC for the design-build of the U.S. Embassy in Ulaanbaatar, Mongolia, representing a civilian (non-defense) infrastructure investment. This large, competitively won contract signals a stable revenue stream for Caddell over roughly 5.3 years, but the firm-fixed-price structure and complex foreign construction expose the company to execution risk. The highest-conviction signal is the revenue visibility, while the key watch item is Caddell's margin performance and project milestones given the high-risk pricing model.

New Federal Contractors — September 04, 2026

The six contracts analyzed total $1.34 billion in obligations, with a civilian-heavy split (4 of 6 contracts, ~$1.33B) versus defense-related awards (2 of 6, ~$222M). The dominant theme is federal investment in infrastructure and IT services, led by a $484.2M State Department embassy construction award to Caddell Construction and a $357.9M USAID trade initiative contract to DAI Global. The highest-conviction signal is Caddell's large, competitively won fixed-price contract, which offers a multi-year revenue stream but carries execution risk. Key watch items include the potential recompetition of ATCC's expired NIH biodefense repository contract and the unusual negative outlay on ManTech's GSA network defense award.

6 total filings

Significant Contract Modifications ($10M+) — September 04, 2026

The six contracts analyzed, totaling $1.34B in obligations, are overwhelmingly civilian (4 of 6), with only two defense-related awards (Lockheed Martin at $1.5M and a DHS Coast Guard contract). The dominant theme is State Department and USAID infrastructure and development spending, led by Caddell Construction's $484M embassy build in Mongolia and DAI Global's $358M trade initiative. The highest-conviction signal is Caddell's full-and-open competitive win on a large firm-fixed-price contract, which carries execution risk on a complex overseas project. A key risk is the expired or underperforming status of several contracts (ATCC, Guidehouse, ManTech), suggesting limited current revenue visibility from these awards. Investors should watch for recompete announcements for the ATCC biodefense repository and ManTech's E DEFEND network defense program as potential catalysts.

6 total filings